Hot Life Science Investor Mandate 3: South Korean Pharmaceutical Company Seeking to In-License Clinical Stage Therapeutics in Neurology, Hepatology, and Gastroenterology

12 Mar

A South Korean pharmaceutical company that specializes in Gastrointestinal, CNS, and Metabolic products is actively searching for promising therapeutic candidates under development around the world to incorporate into its pipeline. The company is flexible in terms of the structure, but mostly in-licensing or co-development. The company is interested in world wide/major territories such as the US, EU, APAC, and East Asia. 

The firm is currently seeking promising therapeutic candidates to incorporate into its pipeline. The company is most interested in neurology, hepatology, and gastroenterology. However, the firm is also interested in other therapeutic areas that address large unmet medical needs. The company will look at both small molecules and biologics and will consider only NCE or NCE-like molecules (such as repositioning molecule, new indication, etc). The company prefers assets in phase I, II, or IND-ready. However, the company will also look at assets in phase III and NDA stage.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

One Response to “Hot Life Science Investor Mandate 3: South Korean Pharmaceutical Company Seeking to In-License Clinical Stage Therapeutics in Neurology, Hepatology, and Gastroenterology”

  1. Jenie April 29, 2015 at 12:48 pm #

    that’s great news for Gastroenterology

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: